News | February 16, 2022
Moderna announces expansion in key Asian markets
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
Up to 100 million mRNA vaccine doses could be produced in Australia each year
Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed
She replaces Victoria Tabiner, who is stepping down after 10 years at Sygnature
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
Subscribe To Our Newsletter & Stay Updated
